Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci  by Kara, Ahu et al.
b r a z j i n f e c t d i s . 2 0 1 5;1  9(1):58–61
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
Original article
Risk  of  vancomycin-resistant  enterococci
bloodstream infection  among  patients  colonized
with vancomycin-resistant  enterococci
Ahu Karaa,∗, I˙lker Devrima, Nuri Bayrama, Nagehan Katipog˘lub, Ezgi Kıranb,
Yeliz  Oruc¸ c, Nevbahar Demirayc, Hurs¸it  Apab, Gamze Gülﬁdand
a Department of Pediatric Infectious Disease, Dr. Behc¸et Uz Children’s Hospital, I˙zmir,  Turkey
b Department of Pediatrics, Dr. Behc¸et Uz Children’s Hospital, I˙zmir,  Turkey
c Hospital Infection Control Committee, Dr. Behc¸et Uz Children’s Hospital, I˙zmir,  Turkey
d Department of Clinical Microbiology, Dr. Behc¸et Uz Children’s Hospital, I˙zmir,  Turkey
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 29 May 2014
Accepted  17 September 2014
Available  online 18 December 2014
Keywords:
Bloodstream infections
Colonization
Immunosupression
Vancomycin-resistant enterococcus
a  b  s  t  r  a  c  t
Background: Vancomycin-resistant enterococci colonization has been reported to increase
the  risk of developing infections, including bloodstream infections.
Aim:  In this study, we aimed to share our experience with the vancomycin-resistant entero-
cocci bloodstream infections following gastrointestinal vancomycin-resistant enterococci
colonization  in pediatric population during a period of 18 months.
Method:  A retrospective cohort of children admitted to a 400-bed tertiary teaching hospital
in  Izmir, Turkey whose vancomycin-resistant enterococci colonization was newly detected
during  routine surveillances for gastrointestinal vancomycin-resistant enterococci colo-
nization  during the period of January 2009 and December 2012 were  included in this study.
All vancomycin-resistant enterococci isolates found within 18 months after initial detection
were  evaluated for evidence of infection.
Findings: Two hundred and sixteen patients with vancomycin-resistant enterococci were
included  in the study. Vancomycin-resistant enterococci colonization was detected in 136
patients  (62.3%) while they were hospitalized at intensive care units; while the remaining
majority  (33.0%) were hospitalized at hematology-oncology department. Vancomycin-
resistant  enterococci bacteremia was present only in three (1.55%) patients. All these
patients  were immunosuppressed due to human immunodeﬁciency virus (one patient) and
intensive chemotherapy (two patients).
Conclusion: In conclusion, our study found that 1.55% of vancomycin-resistant enterococci-
colonized  children had developed vancomycin-resistant enterococci bloodstream infection
among  the pediatric intensive care unit and hematology/oncology patients; according to ourﬁndings, we suggest that
resistant  enterococci bloo
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he emergence and spread of vancomycin-resistant entero-
occi  (VRE) as a nosocomial pathogen represent a major health
roblem  since its ﬁrst isolation in the United Kingdom and in
rance.1,2 Recent articles reported a double digit number of
ospitalizations for VRE infections between 2003 and 2006.3
Colonization is the key point for VRE infections. Infections
enerally follow VRE colonization mostly in gastrointestinal
ract.4 VRE colonization was  reported to increase a patient’s
isk  of developing infections, such as bloodstream infections
BSIs).5,6 Another study reported a 5- to 10-fold increased risk
f  infection once a patient was  colonized with VRE.7 The
RE  infection rates were  highest in hematologic–oncologic
atients, organ transplant recipients and patients in intensive
are  units while it is reported to be nearly zero in immunocom-
etent patients. However, studies including children with VRE
nfections following gastrointestinal VRE colonization were
are  and most data were adopted from adult studies.5,6,8–11
In this study, we  report our experience with the VRE blood-
tream  infections following gastrointestinal VRE colorizations
or  an 18-month period.
aterials  and  methods
his retrospective study was  conducted in Dr. Behc¸et  Uz Chil-
ren’s  Hospital, a 400-bed tertiary teaching hospital in Izmir,
urkey,  between January 2009 and December 2012. Patients
ith  newly  detected VRE colonization during routine surveil-
ances  for gastrointestinal VRE colonization were included in
his study.
In  our center; rectal sample screening for VRE was  per-
ormed  at admission and weekly in all intensive care units
ICUs);  hematology–oncology department and neonatal inten-
ive  care unit using conventional cultures and molecular
iagnostic techniques. The “red ﬂag” precautions for patients
ith  VRE colonization were  also performed and strict infection
ontrol  policies as part of patient management were applied
n  our center.
Using  the VRE colonized patients cohort, we observed all
he  patients during 18 months after initial detection using
n-patient and outpatient medical records at the same insti-
ution.  The patients’ age, gender, service where patient was
ospitalized,  re-hospitalization, episodes of bacteremia, and
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isolated microorganism were recorded. Medical records were
reviewed  to identify the body site that had been colonized
or  infected when the initial VRE-positive culture sample was
obtained  and whether the detection represented colonization
or  infection on the basis of the Centers for Disease Control and
Prevention  criteria.12
All VRE isolates found within 18 months after initial detec-
tion  were evaluated for evidence of discrete infection. Two
trained  reviewers separately veriﬁed whether infections rep-
resented  distinct and unrelated events. Subsequent infections
were  described according to the infection site and days since
initial  detection. We determined the proportion of patients
who  subsequently developed VRE infection within the study
cohort.  The investigators obtained further information about
the  patients’ complaints by calling the patients’ family.
VRE  detection: rectal swabs were  directly inoculated onto
a  chromogenic agar plate (ChromID VRE agar bioMérieux,
France) containing 8 mg  of vancomycin ml−1 and incubated
at  36 ◦C aerobically for 72 h. Identiﬁcation and antibiotic sus-
ceptibility  tests were performed using the automated VITEK-2
system  (bioMérieux, France) via Gram positive identiﬁcation
card,  AST-P592, a supplementary E-test (bioMérieux, Durham,
NC)  and disk diffusion test according to the manufacturer’s
instructions. Van A and Van B resistance phenotypes were
reported  by the system on the basis of MIC values.
Statistical analysis was  performed by using the Statistical
Package for the Social Science (SPSS) software. Distribution of
numeric  variables was  tested by both graphical methods and
Shapiro–Wilk  test. The difference between means of numeric
variables  was  tested by Student’s t test or Mann–Whitney U
test,  where appropriate. The difference between proportions
was  tested by Chi-Square or Fisher’s exact test. p < 0.05 was
considered statistically signiﬁcant.
Results
Two hundred and sixteen patients with VRE colonization were
included  in the study. The median age of the patients was  two
months  ranging from 14 days to 16 years. One hundred and
forty  patients were male (64.2%).
Colonization was  detected in 136 patients (62.3%) while
they  were  hospitalized at ICUs, and 71 patients (33.0%) were
hospitalized at the hematology–oncology department.
Neonatal ICU
Oncology-hematology
department
Pediatric ICU
Pediatric Infectious
Disease Department
Cardiovascular surgery ICU
Pediatric Surgery ICU
Pediatric Burn Unit
of bacteremia during the study period.
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During the study period of 18 months, 17 VRE colonized
patients identiﬁed in the ﬁrst year of hospitalization and six
patients  who  had been hospitalized in other centers for fever
were  not included in the analysis.
During the study period a total of 103 bacteria were iso-
lated.  Seventeen coagulase-negative staphylococci isolates
were  deemed to be contamination as they had been isolated
only  in one bottle of the culture sets. Among the 86 isolated
microorganims, the most isolated bacteria was coagulase-
negative staphylococci (32.5%), followed by Candida parapsilosis
(12.7%),  Escherichia coli (11.6%) and Klebsiella species (9.3%)
(Fig.  1). Out of the 193 colonized VRE patients, VRE bacteremia
was  present only in three (1.55%) patients.
The three patients who had VRE bacteremia episodes
were  a 4-month old girl who had perinatal human immu-
nodeﬁciency virus (HIV) infection, a 6-year old boy who had
been  under intensive chemotherapy for acute myeloblastic
leukemia, and a 7-year old girl under acute lymphoblastic
leukemia.
Discussion
Enterococci were reported to be the third most common organ-
ism  causing BSI in hospitalized children.13,14 However, in
our  clinical experience, we have witnessed few VRE associ-
ated  BSI. This retrospective study was  designed to review our
experience  with VRE associated BSI following VRE-colonized
patients and to identify risk factors associated with VRE BSI
infection.
In  our study, most patients with VRE colonization were
neonates and pediatric hematology–oncology patients fol-
lowed  by patients in intensive care units. VRE colonization
in  Neonatal ICU (NICU) was  reported more  occasionally com-
pared  to the two wards  above.15–19 In addition to the NICU, VRE
colonization has been well-deﬁned in pediatric hematology-
oncology wards  supporting our ﬁndings.20–22
In our study; the rate of VRE BSI among colonized patients
was  1.55%, which was  lower than the majority of reports sug-
gesting  VRE BSI rates ranging from 0% to 45% among colonized
individuals, depending on the population studied.9,10,23–32
Brennen et al.23 reported that no VRE BSI was  recorded in 36
colonized  residents of a long-term care facility, supporting the
variability  of VRE BSI. In a study, including 52 patients with VRE
colonization, two patients were  reported to have VRE BSI.30
A recent study from Taiwan reported only two patients with
VRE  BSI out of 47 patients who acquired VRE during their ICU
stays.31
Adult patients are more  likely to have more  serious comor-
bid  conditions reported to increase VRE colonization and
infections.32 However, a previous study including 768 patients
reported  that only 31 (4.0%) of the patients had VRE BSI.32
Moreover, 13.4% of the adult patients with malignancies and
VRE  colonization were reported to develop VRE BSI suggesting
that  malignancy is an important risk factor for VRE-BSI.9 Com-
paring  to these adult studies, children had shown the same
pattern  of adults but with a low rate of VRE BSI development.
Two of our hematology–oncology patients and one HIV
infected child had signiﬁcant degree of immunosupression.
Previous studies reporting higher rates of VRE BSI among 0 1 5;1  9(1):58–61
colonized solid organ transplant patients (6.3–11.5%),27–29 col-
onized  patients with cancer (13.4–29.3%),9,24,25 colonized bone
marrow  transplant recipients (26.7–34.2%),31,32 and colonized
patients (45%)33 supported our ﬁndings. Immunosuppressed
patients were reported to be a special risk group for severe
VRE  infections.11,34 Matar et al.25 reported that, among 99
VRE-colonized patients with cancer, 29 (29.3%) developed VRE
BSI, and the majority of these (71%) were  neutropenic at the
time  they developed their infection. Zaas et al.9 reported that,
among  colonized cancer patients, diabetes mellitus, under-
going  a gastrointestinal procedure, acute renal failure, and
exposure  to vancomycin were signiﬁcant risk factors for devel-
oping  VRE BSI.
Since  hematology–oncology patients were found to have
VRE  associated BSI more  intense precautions should be taken
in  these wards, as recommended by the Society for Health-
care  Epidemiology of America35 and by the Centers for Disease
Control  and Prevention in hematology–oncology guidelines.36
This study is limited by its retrospective design and
unavailability of subtyping VRE by pulsed-ﬁeld gel elec-
trophoresis. Since data regarding the risk of VRE BSI among
children  are limited our ﬁndings will be helpful in discrimi-
nating  risk groups for developing VRE BSI.
In conclusion, our study found that 1.55% of VRE-colonized
children had developed VRE BSI. According to our ﬁndings,
Pediatric ICU and hematology/oncology patients are under
higher  risk for VRE colonization, and immunosuppression is
the key point for developing VRE bloodstream infections.
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